Frazier Life Sciences’ Post

📰 Weekly Healthcare & Life Sciences transactions selection: GREENPEAK Partners-backed Paratus (🇩🇪) secures majority ownership in DB Soft (🇪🇸). Resolve Stroke (🇫🇷) raises €2.2m with Quantonation and OVNI Capital. Broken String Biosciences (🇩🇪) closes $15M Series A Funding Round co-led by Illumina Ventures and Merieux Equity Partners. Pharmanovia (🇬🇧) acquire 11 central nervous system brands from Sanofi (🇫🇷). ReCode Therapeutics (🇺🇸) announced the closing of an extension to its Series B financing, raising an additional $50m with new investor Bioluminescence Ventures and Solasta Ventures. MCH Private Equity has invested in FARMALIDER GROUP (🇪🇸). REEV (techstars '23) (🇫🇷) raises €3m from Polytechnique Ventures, IRDI Capital Investissement, and Newfund. Search your next deal among #privateequity #investments and millions of company profiles on Tsylana app for #investmentbanking #corporatefinance and #capitalinvestissement professionals.

With the scorched earth of recent pharma launches, it makes you ask, "if we hire great people, have stellar leaders, and a unique value proposition, will it make a difference?" Answer- YES. Congrats to Axsome Therapeutics, Inc. on their full year results... launch year results, that is! Watching their initial commercial build- they got some amazing people (Mark Podkladek, Elizabeth Carveth Nunes, Brad Raudabaugh Stacy Wilson and David Jenkins, MSOL, Ed.D as just few examples of many). Then they expanded- which is a telling move. Because a company's initial behaviors speak to the marketplace of talent- which controls who is willing to show up. As my old boss would say, we don't want sh*tbirds, we need eagles. They got eagles. So a hat-tip to Axsome for betting on people to get it right. If the people don't believe in the company or the product, no customer should or will believe the message enough to offer that product to patients. Lesson- in the crazy biz of biotech... yes, the good folks can win. #pharma #biotech #launch #peoplefirst

#Partnerships with external investors like Tesi are crucial for BC Platforms' growth and internationalization. 🚀 #data #drugdevelopment #healthcare #precisionmedicine #healthtech #healthtechinnovation

Thrilled to share the launch of Spinnaker Life Sciences Strategy Consulting! Brooks Hill Partners, Red Team Associates, and Solstice Strategy Group have joined forces to form Spinnaker Life Sciences Strategy Consulting with offices located in Boston and Minneapolis. The merger marks a strategic alliance that combines the strengths, expertise, and innovative approaches of three industry leaders to help pharmaceutical, biotech, and med-tech companies navigate smarter strategies during the current challenging capital and commercialization life sciences environment. Looking forward to seeing what's to come! Learn more at www.spinnakerLS.com #healthcareconsulting #lifesciences #consulting #strategyconsulting #healthcare #pharmaceutical #biotechnology #medicaldevices #venturecapital #vc #vcfunding #startup #fundraising #digitalhealth #healthtech #healthcareindustry #partnerships #healthcarerecruiting #latestnews #healthcarecareer

🎉 Big News Announcement! 🎉 Over a year ago, Dane Callow, Harris Kaplan, and I embarked on a journey to create something truly special—a consulting firm tailored for the intricate and ever-changing life sciences landscape. Today, I couldn't be more thrilled to announce the launch of our new firm - Spinnaker Life Sciences Strategy Consulting! With offices in Boston and Minneapolis, we're dedicated to empowering pharmaceutical, biotech, and med tech companies to thrive amidst the complexities of today's capital and commercialization challenges. 🚀 Our Mission: At Spinnaker, we're not just consultants—we're partners on your journey to success. Whether you're navigating regulatory hurdles, optimizing your product portfolio, or seeking to maximize revenues, we're here to support you every step of the way. 💼 Connect With Us: Ready to explore how Spinnaker can elevate your organization? Head to our website (spinnakerls.com) to learn more (or even better—reach out to me directly!) #LifeSciences #Consulting #Innovation #SpinnakerLS

Launched by veteran biotech venture capitalist Alexis Borisy, EQRx started up in early 2020 with grand plans to reimagine how prescription drugs are developed and priced. The company claimed it could invent or license similar, but more effective competitors to top-selling specialty medicines, such as those for cancer, and sell them for less — a vision EQRx executives used to raise more than $2 billion in funding. REVOLUTION Medicine is a University of Illinois Urbana-Champaign start-up created under EnterpriseWorks in 2014 as a company funded by Illinois Ventures and Third Rock with superstar faculty Martin D. Burke, Michael Fischbach, and Kevan Shokat (UCSF) originally developing low toxicity Amphotericin analogs. But a reorganization saw the Ampho technology returned to the university (Relicensed to Deerfield Partners) as REVOLUTION repositioned itself by purchasing a KRAS biotech company. Now with the merger REVOLUTION acquires a massive amount of cash to develop in in-licensed technologies. https://lnkd.in/gA9bfjAz

ClavystBio CEO Khoo Shih sat down with Citeline Commercial Scrip’s Mandy Jackson to discuss the growing traction in the biotech market. Financing is showing signs of improvement, driven by increased M&A activity from big pharma acquiring smaller firms at attractive valuations. IPOs for clinical-stage companies are also on the rise. Khoo Shih highlighted that while financing prospects are improving, success hinges on companies with a well-articulated story and clear milestones: Key takeaways: • Clarity in Milestones: This is a pivotal time for biotechs to sharpen strategies and communicate their milestones. Investors are looking for companies that can articulate a clear path to value-creating clinical milestones. • Platform Potential: While platforms are valued, the real focus is on the progression of drug candidates. • Strong Insider Commitment: Demonstrating robust internal support is crucial. Read the full article here (for subscribers only): https://lnkd.in/g7DZjZwz

Yesterday afternoon, Trulitica and The Social Coyote crossed paths at LaunchBio Inc.'s Larger Than Life Series. At this event, the focus was on strategic outsourcing. We heard from leaders at MaxSynergy Consulting, LLC Evotec Turnstone Biologics Gen2x, llc. 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 1) Outsourcing is a lifeline for capital constrained startups 2) Key challenges in outsourcing are employee turnover and loss of project continuity 3) Quality is more important than cost 4) Successful collabs are treated as partnerships 5) Don't skimp on legal counsel...even if you're cash strapped 6) Consider tech transfer challenges when outsourcing offshore (language, time zone, culture) 𝗦𝗵𝗼𝘂𝘁 𝗼𝘂𝘁𝘀 Thank you to Melissa Schmidt & team as well as sponsors for making this event possible. Shout out to Jonah Peake 🐺 and The Social Coyote for making us aware of this event! Looking forward to the next series. #consulting, #biotechnology, #innovation ⭐And as always - if you want independent 3rd party auditing of your product feasibility & development. Visit our website & schedule a call!

What if you could tap into additional expertise to help drive your drug discovery programs - would you be interested? Please reach out to Jackie Macritchie, Chris Hurley or Justin Bryans if you would like more information about Discovery | Charles River #drugdiscovery #lifeatCRL Static copy in the comment section.

Dealmaking has hit biopharma front and center this year. 2024 is off to a great start with all the M&A and BD deal announcements leading up to the J.P. Morgan Healthcare Conference. With all the trials and tribulations biotech founders go through, M&A shines as the bright light at the end of the tunnel. Of course the announcements are the tip of the iceberg. A milestone achieved after months of engagement to find the right fit and the right partner.   If you have been following the space or looking for a recap, here is a list of deals announced so far this month. Here's to hoping for many more successful M&A exits this year!   #biotech #biopharma #dealmaking #jpm2024